BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38890442)

  • 1. FLI1 is associated with regulation of DNA methylation and megakaryocytic differentiation in FPDMM caused by a RUNX1 transactivation domain mutation.
    Tanaka Y; Nakanishi Y; Furuhata E; Nakada KI; Maruyama R; Suzuki H; Suzuki T
    Sci Rep; 2024 Jun; 14(1):14080. PubMed ID: 38890442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired hematopoietic differentiation of RUNX1-mutated induced pluripotent stem cells derived from FPD/AML patients.
    Sakurai M; Kunimoto H; Watanabe N; Fukuchi Y; Yuasa S; Yamazaki S; Nishimura T; Sadahira K; Fukuda K; Okano H; Nakauchi H; Morita Y; Matsumura I; Kudo K; Ito E; Ebihara Y; Tsuji K; Harada Y; Harada H; Okamoto S; Nakajima H
    Leukemia; 2014 Dec; 28(12):2344-54. PubMed ID: 24732596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone Marrow Morphology Associated With Germline
    Chisholm KM; Denton C; Keel S; Geddis AE; Xu M; Appel BE; Cantor AB; Fleming MD; Shimamura A
    Pediatr Dev Pathol; 2019; 22(4):315-328. PubMed ID: 30600763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GENYOi005-A: An induced pluripotent stem cells (iPSCs) line generated from a patient with Familial Platelet Disorder with associated Myeloid Malignancy (FPDMM) carrying a p.Thr196Ala variant.
    Lamolda M; Montes R; Simón I; Perales S; Martínez-Navajas G; Lopez-Onieva L; Ríos-Pelegrina R; Del Moral RG; Griñan-Lison C; Marchal JA; Lozano ML; Ramos-Mejia V; Rivera J; Bastida JM; Real PJ
    Stem Cell Res; 2019 Dec; 41():101603. PubMed ID: 31698193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RUNX1 deficiency (familial platelet disorder with predisposition to myeloid leukemia, FPDMM).
    Schlegelberger B; Heller PG
    Semin Hematol; 2017 Apr; 54(2):75-80. PubMed ID: 28637620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RUNX1, but not its familial platelet disorder mutants, synergistically activates PF4 gene expression in combination with ETS family proteins.
    Okada Y; Watanabe M; Nakai T; Kamikawa Y; Shimizu M; Fukuhara Y; Yonekura M; Matsuura E; Hoshika Y; Nagai R; Aird WC; Doi T
    J Thromb Haemost; 2013 Sep; 11(9):1742-50. PubMed ID: 23848403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted gene correction of RUNX1 in induced pluripotent stem cells derived from familial platelet disorder with propensity to myeloid malignancy restores normal megakaryopoiesis.
    Iizuka H; Kagoya Y; Kataoka K; Yoshimi A; Miyauchi M; Taoka K; Kumano K; Yamamoto T; Hotta A; Arai S; Kurokawa M
    Exp Hematol; 2015 Oct; 43(10):849-57. PubMed ID: 26021490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RUNX-1 haploinsufficiency causes a marked deficiency of megakaryocyte-biased hematopoietic progenitor cells.
    Estevez B; Borst S; Jarocha D; Sudunagunta V; Gonzalez M; Garifallou J; Hakonarson H; Gao P; Tan K; Liu P; Bagga S; Holdreith N; Tong W; Speck N; French DL; Gadue P; Poncz M
    Blood; 2021 May; 137(19):2662-2675. PubMed ID: 33569577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human
    Li Y; Jin C; Bai H; Gao Y; Sun S; Chen L; Qin L; Liu PP; Cheng L; Wang QF
    Blood; 2018 Jan; 131(2):191-201. PubMed ID: 29101237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted correction of RUNX1 mutation in FPD patient-specific induced pluripotent stem cells rescues megakaryopoietic defects.
    Connelly JP; Kwon EM; Gao Y; Trivedi NS; Elkahloun AG; Horwitz MS; Cheng L; Liu PP
    Blood; 2014 Sep; 124(12):1926-30. PubMed ID: 25114263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A RUNX1-FPDMM rhesus macaque model reproduces the human phenotype and predicts challenges to curative gene therapies.
    Lee BC; Zhou Y; Bresciani E; Ozkaya N; Dulau-Florea A; Carrington B; Shin TH; Baena V; Syed ZA; Hong SG; Zhen T; Calvo KR; Liu P; Dunbar CE
    Blood; 2023 Jan; 141(3):231-237. PubMed ID: 36322931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered platelet-megakaryocyte endocytosis and trafficking of albumin and fibrinogen in RUNX1 haplodeficiency.
    Del Carpio-Cano F; Mao G; Goldfinger LE; Wurtzel J; Guan L; Alam MA; Lee K; Poncz M; Rao AK
    Blood Adv; 2024 Apr; 8(7):1699-1714. PubMed ID: 38330198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations.
    Antony-Debré I; Bluteau D; Itzykson R; Baccini V; Renneville A; Boehlen F; Morabito M; Droin N; Deswarte C; Chang Y; Leverger G; Solary E; Vainchenker W; Favier R; Raslova H
    Blood; 2012 Sep; 120(13):2719-22. PubMed ID: 22677128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RUNX1 and TGF-β signaling cross talk regulates Ca
    Raghuwanshi S; Dahariya S; Sharma DS; Kovuru N; Sahu I; Gutti RK
    FEBS J; 2020 Dec; 287(24):5411-5438. PubMed ID: 32281291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of inherited thrombocytopenia resulting from mutations in ETV6 or RUNX1 using a human pluripotent stem cell model.
    Borst S; Nations CC; Klein JG; Pavani G; Maguire JA; Camire RM; Drazer MW; Godley LA; French DL; Poncz M; Gadue P
    Stem Cell Reports; 2021 Jun; 16(6):1458-1467. PubMed ID: 34019812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enrichment of FLI1 and RUNX1 mutations in families with excessive bleeding and platelet dense granule secretion defects.
    Stockley J; Morgan NV; Bem D; Lowe GC; Lordkipanidzé M; Dawood B; Simpson MA; Macfarlane K; Horner K; Leo VC; Talks K; Motwani J; Wilde JT; Collins PW; Makris M; Watson SP; Daly ME;
    Blood; 2013 Dec; 122(25):4090-3. PubMed ID: 24100448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic landscape of patients with germline RUNX1 variants and familial platelet disorder with myeloid malignancy.
    Yu K; Deuitch N; Merguerian M; Cunningham L; Davis J; Bresciani E; Diemer J; Andrews E; Young A; Donovan F; Sood R; Craft K; Chong S; Chandrasekharappa S; Mullikin J; Liu PP
    Blood Adv; 2024 Jan; 8(2):497-511. PubMed ID: 38019014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia.
    Martens JH; Mandoli A; Simmer F; Wierenga BJ; Saeed S; Singh AA; Altucci L; Vellenga E; Stunnenberg HG
    Blood; 2012 Nov; 120(19):4038-48. PubMed ID: 22983443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NF-E2, FLI1 and RUNX1 collaborate at areas of dynamic chromatin to activate transcription in mature mouse megakaryocytes.
    Zang C; Luyten A; Chen J; Liu XS; Shivdasani RA
    Sci Rep; 2016 Jul; 6():30255. PubMed ID: 27457419
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.